Overview of Dr. Donahue
Dr. Timothy Donahue is an urologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Boston University School of Medicine and has been in practice 22 years. He is one of 73 doctors at Memorial Sloan Kettering Cancer Center and one of 16 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Urology. He has more than 50 publications and over 500 citings.
Office
353 East 68th Street
New York, NY 10065
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2012 - 2014
- National Capital ConsortiumResidency, Urology, 1997 - 2001
- National Capital ConsortiumInternship, Transitional Year, 1995 - 1996
- Boston University School of MedicineClass of 1995
Certifications & Licensure
- NY State Medical License 2012 - 2025
- MD State Medical License 1997 - 2016
Clinical Trials
- Fluorescent Imaging of Nerves With Illuminare-1 During Surgery Start of enrollment: 2021 Oct 04
Publications & Presentations
PubMed
- 29 citationsNeoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.Samuel A Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan
Journal of Clinical Oncology. 2022-04-20 - 51 citationsThe Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical CystectomyQiang Li, Melissa Assel, Nicole Benfante, Eugene J. Pietzak, Harry W. Herr
European Urology Focus. 2017-06-27 - 9 citationsMRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.Andreas G Wibmer, Robert A Lefkowitz, Yulia Lakhman, Joshua Chaim, Ines Nikolovski
Clinical Genitourinary Cancer. 2022-08-01
Press Mentions
- Could Common Blood Pressure Meds Help Curb Pancreatic Cancer?February 25th, 2022
- Combination Therapy Suppresses Pancreatic Tumour Growth: StudyFebruary 25th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: